We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
The need to untangle differences in business culture, politics and regulation means the region’s legal sector is open up to experimentation
Bluebell Capital Partners calls for conglomerate’s break-up and boardroom reshuffle ahead of AGM
Conglomerate faces ‘unique challenges’ but separating pharma and agrichemical units not a done deal
Companies are ‘at the mercy of an industry of litigation lawyers’, says outgoing CEO Werner Baumann
But high-profile shareholder may not be satisfied with informal position
He will replace embattled boss Baumann who has faced criticism from disgruntled investors
Ubben believes more could be done to isolate the liability to Roundup
German group’s drugs chief warns EU and UK are dissuading investment as company prioritises US and China
Also in today’s newsletter, the ‘new normal’ of huge natural disaster losses
Inclusive Capital takes €400mn stake as German group grapples with legacy of Monsanto takeover
German group offers strengths in difficult economic times but outlook is darkened by US legal cases
Awards highlights include: digitisation, the client experience, and the most innovative law firms and individuals
We highlight the evolving role of senior in-house lawyers by showcasing outstanding examples of wide-ranging leadership skills
Rising global food prices after Russian invasion of Ukraine spur group’s crop sciences business
Judges decline to hear appeal by German group over case in which weedkiller customer was awarded $25mn
Essential products delivered this season but next year in doubt
Lawyers tackled legal and data privacy issues to deliver Covid test kits in the UK
German drugs group to snap up biopharmaceuticals group in innovation push
German drugmaker believes jab could still be used for some age groups or as booster
Chemical group says it wants to reduce risk of litigation after court dismisses $2bn plan to settle cancer claims
German group expects new drugs to plug revenue gap as it pledges to increase profits
Stefan Oelrich acknowledges challenge of its two bestselling products going off patent
Collaboration will help German group deliver several hundred million doses after lagging behind competitors
Paying up to $4bn for US-based biotech is unlikely to be transformational
German group acquires US-based AskBio to strengthen its lucrative pharma business
International Edition
